Acquisci Inc. is a privately held company that has recently acquired a medical device-based proprietary multi-therapeutic platform; doseabable-Oxidative Stressed Autologous Blood (d-OSAB), a systemic anti-flammatory treatment of cardiovascular diseases wherein inflammation is an underlying etiology. The Company's inital clinical inflammatory-based targets are Ischemic Brain Stroke and Chronic Heart Failure, two diseases with few viable treatment options. d-OSAB represents a novel re-engineered formulation based on unregulated traditional therapies., which have been used for more than 20 years and generated a safety profile of non-toxicity in more than five million treatments delivered to more than 35,000 patients. However, previous therapies utilized impercise technologies not suitable for FDA or European regulatory clearance for commercial marketing. d-OSAB includes a regulartory-approvable patent pending therapeutic contact device, among other proprietary advantages, allowing for percise dose measurements and control. Additional applications of the d-OSAB platform include a purification process for the producation of pathogen-free biologics, most notably inactivating infectious prions, the rogue protein atttributed to Mad Cow and Creutzfeldt-Jakob diseases.